BIOTRONIK Logo
2012-06-14 15:37
Endosense and BIOTRONIK Announce CE Mark Approval, First Clinical Use of the New TactiCath(R) Quartz Force-Sensing Ablation Catheter
GENEVA AND BERLIN--(Korea Newswire) June 14, 2012 -- Endosense and BIOTRONIK SE & Co. KG have announced that Endosense's TactiCath® Quartz force-sensing ablation catheter has been CE mark approved in Europe. First cases using the new device have been performed by renowned physicians at three centers across Europe: Dr. D. Shah from University Hospital of Geneva, Dr. G. Nölker from Heart and Diabetes Center in Bad Oeynhausen, Dr. R. Wakili and Dr. H. Estner from University Hospital Grosshadern in Munich.

The TactiCath® Quartz is a third generation device that brings a host of technical and practical advancements to the electrophysiology lab. Key innovations include a new force sensor that provides increased stability and precision and avoids pre-procedure calibration; a small equipment footprint for easier lab integration; a user friendly graphical interface; and, enhanced signal processing and digital output that facilitates connectivity with imaging devices and other equipment in the lab.

“As a long-time user of the TactiCath®, I find the Quartz generation to be another significant improvement in the field,” said Dr. Shah. “The new force sensor technology gives me even greater confidence in the accuracy of the force signal. In addition, the 50Hz sampling rate dramatically increases precision of the display and gives me every detail of the force applied in real time.”

Also new to the TactiCath® Quartz is a breakthrough Lesion Index (LSI) parameter that provides an improved, real-time indication of lesion quality during catheter ablation procedures. Pioneered by Endosense, LSI is a sophisticated algorithm that correlates lesion formation with radiofrequency power, ablation time and contact force. Clinical data presented at Heart Rhythm 2012 showed that LSI is so far the best available parameter to predict risk for reconnection after pulmonary vein isolation (PVI), with high statistical significance.

The TactiCath® Quartz is an innovation born from more than two years of extensive commercial experience with earlier TactiCath® devices; Endosense believes this third generation device will set the new standard in the field.

The TactiCath® Quartz is CE mark approved for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). The new device and its accompanying TactiSys system are available commercially in Europe through Endosense's distribution partner BIOTRONIK.

About BIOTRONIK SE & Co. KG
As one of the world's leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of over 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.

About Endosense
Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.

Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.

Upon publication, please provide us with a copy.
  • Media Contact
  • BIOTRONIK Contact Global:
    Sandy Hathaway
    Senior Director, Global Communications
    BIOTRONIK SE & Co. KG
    +49 (0) 30 68905 1602
    Email 보내기

    ENDOSENSE Media
    Contact/U.S.:
    Laura Nobles
    Nobles Communications
    +1 310-795-0497
    Email 보내기

    ENDOSENSE Media
    Contact/Europe:
    Daniele Castle
    Genevensis Communications
    +41 79 202 6667
    Email 보내기
BIOTRONIK 전체 보도자료 보기
이 뉴스는 기업이 뉴스와이어를 통해 발표한 보도자료입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

BIOTRONIK Contact Global:
Sandy Hathaway
Senior Director, Global Communications
BIOTRONIK SE & Co. KG
+49 (0) 30 68905 1602
Email 보내기

ENDOSENSE Media
Contact/U.S.:
Laura Nobles
Nobles Communications
+1 310-795-0497
Email 보내기

ENDOSENSE Media
Contact/Europe:
Daniele Castle
Genevensis Communications
+41 79 202 6667
Email 보내기
http://www.biotronik.com

이 보도자료 관련 분야

건강  의료기기  조사연구  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.